HLA-A*0301 KRAS G12V Complex Protein, Human (HEK293, His-Avi)

HLA-A*0301 collaborates with B2M to present viral and tumor peptides that direct CD8-positive T cells to respond against infected or transformed cells. It can also present self-peptides to avoid self-reaction. HLA-A*0301 KRAS G12V Complex Protein, Human (HEK293, His-Avi) is a recombinant protein dimer complex containing HLA-A*0301 and B2M/Beta-2-microglobulin Protein, expressed by HEK293 , with C-Avi, C-His labeled tag and VVGAVGVGK peptide. HLA-A*0301 KRAS G12V Complex Protein, Human (HEK293, His-Avi), has molecular weight of 55-60 kDa.

HLA-A*0301, a critical antigen-presenting major histocompatibility complex class I (MHCI) molecule, collaborates with B2M/beta 2 microglobulin to predominantly display viral and tumor-derived peptides on antigen-presenting cells. This presentation allows recognition by alpha-beta T cell receptor (TCR) on HLA-A-restricted CD8-positive T cells, thereby guiding antigen-specific T cell immune responses to eliminate infected or transformed cells. Additionally, HLA-A*0301 may present self-peptides derived from the signal sequence of secreted or membrane proteins, although T cells specific for these peptides are typically inactivated to prevent autoreactivity. The recognition of both the peptide and the MHC molecule by TCR underscores the fine specificity of antigen recognition, with the peptide responsible for this specificity and MHC residues accounting for the MHC restriction of T cells. HLA-A*0301 typically presents intracellular peptide antigens of 8 to 13 amino acids resulting from cytosolic proteolysis via IFNG-induced immunoproteasome or via endopeptidase IDE/insulin-degrading enzyme. It can bind different peptides containing allele-specific binding motifs primarily defined by anchor residues at positions 2 and 9. Notably, specific alleles, such as A*01:01 and A*03:01, present a restricted repertoire of peptides, including viral and tumor epitopes, each characterized by distinct motifs and anchors.

Human

HEK293

C-Avi;C-8*His

NP_002107.3 (G25-T305)&P61769 (I21-M119)&VVGAVGVGK

3105  [NCBI]&567  [NCBI]

Approximately 55-60 kDa,based on SDS-PAGE under reducing conditions,due to the glycosylation.

≥ 95%, as determined by Bis-Tris PAGE.

<1 EU/μg, determined by LAL method.